Income seekers shouldn't give up on the stock yet.

Pfizer is a highly respected drug company facing normal industry headwinds.

Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENA Updated follow-up analysis solidifies ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

WASHINGTON, DC - SEPTEMBER 30: Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump as Centers for Medicare & Medicaid Services Mehmet Oz looks on after Trump announced a deal ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions ...